Haridas Viraga, Pean Polidy, Jasenosky Luke D, Madec Yoann, Laureillard Didier, Sok Thim, Sath Sun, Borand Laurence, Marcy Olivier, Chan Sarin, Tsitsikov Erdyni, Delfraissy Jean-François, Blanc François-Xavier, Goldfeld Anne E
aProgram in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA bImmunology Platform, Institut Pasteur du Cambodge, Phnom Penh, Cambodia cInstitut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France dCambodian Health Committee, Phnom Penh, Cambodia eInstitut Pasteur du Cambodge, Epidemiology and Public Health Unit, Phnom Penh, Cambodia fDepartment of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA gFrench National Agency for Research on AIDS and Viral Hepatitis (ANRS), Paris hAssistance Publique - Hôpitaux de Paris, Bicêtre Hospital, Le Kremlin-Bicêtre, France. *Viraga Haridas, Polidy Pean, and Luke D. Jasenosky contributed equally to the writing of this article. †Current address: Univ. Montpellier, INSERM U1058, Department of Infectious and Tropical Diseases, CHRU Nimes, Nimes, France. ‡Current Address: Univ. Bordeaux, Centre INSERM U897, Epidemiologie-Biostatisque, Bordeaux, France. §Current address: Calmette Hospital, Phnom Penh, Cambodia. ¶Current address: UMR INSERM 1087, CNRS UMR_6291, l'Institut du Thorax, Nantes University, Nantes, France.
AIDS. 2015 Jan 28;29(3):263-73. doi: 10.1097/QAD.0000000000000546.
OBJECTIVE: To investigate the impact of tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) upon immunological recovery and the T-cell compartment after initiation of TB and antiretroviral therapy (ART). DESIGN AND METHODS: We prospectively evaluated T-cell immunophenotypes by flow cytometry and cytokines by Luminex assays in a subset (n = 154) of highly immunosuppressed HIV-infected patients with TB from the Cambodian Early versus Late Introduction of Antiretrovirals randomized clinical trial. We compared findings from patients who developed TB-IRIS with findings from patients who did not develop TB-IRIS. Data were evaluated with mixed-effect linear regression, Kaplan-Meier estimates, and Wilcoxon rank-sum tests, and q-values were calculated to control for multiple comparisons. RESULTS: Development of TB-IRIS was associated with significantly greater pre-ART frequencies of HLA-DRCD45ROCD4, CCR5CD4, OX40CD4, and Fas effector memory CD8 T cells, and significantly elevated levels of plasma interleukin (IL)-6, IL-1β, IL-8, and IL-10, and viral load. Post-ART initiation, effector memory CD4 and Fas effector memory CD4 T-cell frequencies significantly expanded, and central memory CD4 T-cell frequencies significantly contracted in patients who experienced TB-IRIS. By week 34 post-TB treatment initiation, effector memory/central memory CD4 T-cell ratios were markedly higher in TB-IRIS versus non-TB-IRIS patients. CONCLUSIONS: A distinct pattern of pre-ART T-cell and cytokine markers appear to poise the immune response of certain patients to develop TB-IRIS. Experience of TB-IRIS is then associated with long-term remodeling of the CD4 T-cell memory compartment towards an effector memory-dominated phenotype. We speculate that these pre and post-ART TB-IRIS-associated immune parameters may contribute to superior immune control of TB/HIV co-infection and better clinical outcome.
目的:探讨结核病相关免疫重建炎症综合征(TB-IRIS)对结核病和抗逆转录病毒治疗(ART)开始后免疫恢复及T细胞亚群的影响。 设计与方法:我们通过流式细胞术前瞻性评估了柬埔寨早期与晚期引入抗逆转录病毒药物随机临床试验中一部分(n = 154)免疫高度抑制的合并结核病的HIV感染患者的T细胞免疫表型,并通过Luminex检测评估了细胞因子。我们比较了发生TB-IRIS的患者与未发生TB-IRIS的患者的研究结果。数据采用混合效应线性回归、Kaplan-Meier估计和Wilcoxon秩和检验进行评估,并计算q值以控制多重比较。 结果:TB-IRIS的发生与ART前HLA-DR⁺CD45RO⁺CD4、CCR5⁺CD4、OX40⁺CD4和Fas效应记忆CD8 T细胞的频率显著更高,以及血浆白细胞介素(IL)-6、IL-1β、IL-8和IL-10水平及病毒载量显著升高有关。开始ART后,经历TB-IRIS的患者中效应记忆CD4和Fas效应记忆CD4 T细胞频率显著增加,而中枢记忆CD4 T细胞频率显著减少。在结核病治疗开始后第34周时,TB-IRIS患者的效应记忆/中枢记忆CD4 T细胞比率明显高于非TB-IRIS患者。 结论:ART前T细胞和细胞因子标志物的独特模式似乎使某些患者的免疫反应易于发生TB-IRIS。经历TB-IRIS与CD4 T细胞记忆亚群长期重塑为以效应记忆为主导的表型有关。我们推测,这些ART前后与TB-IRIS相关的免疫参数可能有助于对结核病/艾滋病合并感染进行更好的免疫控制并带来更好的临床结局。
Transl Cancer Res. 2022-3
Int J Clin Exp Pathol. 2021-6-15
Life (Basel). 2020-10-29
Front Microbiol. 2019-12-17
PLoS One. 2019-4-25
J Acquir Immune Defic Syndr. 2014-4-1
Nat Rev Rheumatol. 2013-2-19